Signe Borgquist
Aarhus University Hospital · Lund University Hospital, Department of Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Signe Borgquist as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07909889 · Semaglutide for Weight Management During Hormone Therapy for Early Breast CancerAarhus University Hospital · not yet recruiting · Breast Cancer (Early Breast Cancer), Obesity · principal investigator
- N/ANCT06623903 · Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine TherapyAarhus University Hospital · unknown · Early Breast Cancer, Metabolic Health, Estrogen Receptor Positive Breast Cancer · principal investigator
- Ph2NCT02958852 · A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast CancerLund University Hospital · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 09:20 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.Breast Cancer Res Treat · 2013200 citationsRCR 5.6
- Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.J Clin Oncol · 2017108 citationsRCR 3.4
- Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.J Transl Med · 201573 citationsRCR 2.2
- Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.J Clin Oncol · 202152 citationsRCR 3.1
- Global Transcriptional Changes Following Statin Treatment in Breast Cancer.Clin Cancer Res · 201551 citationsRCR 1.6
- Measuring mammographic density: comparing a fully automated volumetric assessment versus European radiologists' qualitative classification.Eur Radiol · 201649 citationsRCR 2.1
- 35 citationsRCR 1.4
- Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.Br J Cancer · 202334 citationsRCR 3.6
- CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Ann Oncol · 202124 citationsRCR 1.3
- Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.Int J Cancer · 20247 citationsRCR 1.0